Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer

Table 1 Patient and tumor characteristics n (%)

Characteristics	Total	D2 gastrectomy	No D2 gastrectomy	P value
Age (in years)	53 (40-74)	54 (42-74)	53 (40-69)	0.929
Sex				0.362
Male	23 (79.3)	13 (72.2)	10 (90.9)
Female	6 (20.7)	5 (27.8)	1 (9.1)
Performance status				> 0.999
ECOG 0	2 (6.9)	1 (5.6)	1 (9.1)
ECOG 1	27 (93.1)	17 (94.4)	10 (90.9)
Tumor location				0.172
Upper	7 (24.1)	2 (11.1)	5 (45.4)
Mid	0 (0)	0 (0)	0 (0)
Lower	11 (37.9)	9 (50)	2 (18.2)
Upper-Mid	3 (10.3)	3 (16.7)	0 (0)
Mid-Lower	0 (0)	0 (0)	0 (0)
Upper-Lower	8 (27.6)	4 (22.2)	4 (36.4)
Pathology				0.257
Adenocarcinoma	19 (65.5)	13 (72.2)	6 (54.5)
Signet ring cell carcinoma	6 (20.7)	2 (11.1)	4 (36.4)
Adeno-signet-ring cell carcinoma	4 (13.8)	3 (16.7)	1 (9.1)
Differentiation				0.619
Well differentiated	3 (13)	2 (12.5)	1 (14.3)
Moderately differentiated	10 (43.5)	6 (37.5)	4 (57.1)
Poorly differentiated	10 (43.5)	8 (50)	2 (28.6)
Bormann type				0.311
1	1 (3.4)	0 (0)	1 (9.1)
2	3 (10.3)	3 (16.7)	0 (0)
3	22 (75.9)	13 (72.2)	9 (81.8)
4	3 (10.3)	2 (11.1)	1 (9.1)
AJCC Clinical T stage				0.385
T3	2 (6.9)	2 (11.1)	0 (0)
T4a	20 (69)	11 (61.1)	9 (81.8)
T4b	7 (24.1)	5 (27.8)	2 (18.2)
AJCC Clinical N stage				0.177
N0	6 (20.7)	2 (11.1)	4 (36.4)
N1	6 (20.7)	4 (22.2)	2 (18.2)
N2	16 (55.2)	12 (66.7)	4 (36.4)
N3a	1 (3.4)	0 (0)	1 (9.1)
AJCC Clinical Stage				0.741
2b	5 (17.2)	2 (11.1)	3 (27.3)
3a	3 (10.3)	2 (11.1)	1 (9.1)
3b	18 (62.1)	12 (66.7)	6 (54.5)
3c	3 (10.3)	2 (11.1)	1 (9.1)

AJCC: American joint committee on cancer; ECOG: Eastern cooperative oncology group. Results are presented as median with range in parentheses and number with column percentages in parentheses.

Table 2 Cause for neoadjuvant chemoradiotherapy administration n (%)

Cause	Value
Invasion of distal esophagus	6 (20.7)
Abutment to adjacent organ	10 (34.5)
Invasion of adjacent organ	8 (27.6)
Extensive node metastasis	4 (13.8)
Other	1 (3.4)